Pharmaceutical Manufacturers Association Statement on Global Health
The Pharmaceutical Manufacturers Association of Japan (PMAJ) contributes to improving the health of patients around the world through the discovery, research and development of pharmaceutical products. To ensure that the medicines created through such research and development are delivered to patients safely and reliably, the Pharmaceutical Manufacturers Association of Japan (PMAJ) has issued the following statements.
Achieving Equitable Access in a Pandemic: The Biopharmaceutical Industry's Commitment
In response to the threat of a future global pandemic, the Pharmaceutical Manufacturers Association of Japan (PMAJ), together with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and six other organizations, has developed a set of commitments to ensure equitable access to essential crisis-response and other medicines in future pandemics.
Proposals from the Pharmaceutical Industry for the Health Agenda of the G7 Hiroshima Summit
The Pharmaceutical Manufacturers Association of Japan (PMAJ) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) jointly submitted the "Pharmaceutical Industry Recommendations for the G7 HiroshimaSat Health Agenda" to the Prime Minister, the Minister of Health, Labor and Welfare, the Minister of Finance, and the Minister of Foreign Affairs.
Requests from the Pharmaceutical Industry Regarding the Handover of the Presidency of the G20 Summit
The Pharmaceutical Manufacturers Association of Japan (PMAJ), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA) jointly submitted a "Request from the Pharmaceutical Industry on the Transition of the Presidency of the G20 Summit" to the Ministers of Foreign Affairs and Health of Saudi Arabia, which will host the G20 next year, and Japan, which will host the G20 this year. The Pharmaceutical Manufacturers Association of Japan (PMAJ) submitted the "G20 Health
Recommendations from the Pharmaceutical Industry for the G20 Health Ministers' Meeting
The Pharmaceutical Manufacturers Association of Japan (PAPJ) submitted "Proposals from the Pharmaceutical Manufacturers Association of Japan (PMAJ) for the G20 Health Ministers Meeting" to the Minister of Health, Labour and Welfare.
Pharmaceutical Industry Recommendations for the G20 Osaka Summit Health Agenda
The Pharmaceutical Manufacturers Association of Japan (PAPJ) submitted "Proposals from the Pharmaceutical Industry for the G20 Osaka Summit Health Agenda" to the Prime Minister, the Minister of Health, Labor and Welfare, the Minister of Finance, and the Minister of Foreign Affairs of Japan.
Please click here for more information about the proposal.
- Proposal from the Pharmaceutical Industry to the G20 Osaka Summit Health Agenda (234KB)
- Recommendations from the Pharmaceutical Industry to the Health Agenda of the G20 Osaka Summit (addressed to the Minister of Health, Labour and Welfare) (233KB)
- Recommendations from the Pharmaceutical Industry to the Health Agenda of the G20 Osaka Summit (to the Minister of Finance) (233KB)
- Recommendations from the Pharmaceutical Industry to the Health Agenda of the G20 Osaka Summit (addressed to the Minister of Foreign Affairs) (234KB)
Recommendations from the Pharmaceutical Industry for the G7 Health Ministers' Meeting (Summary)
The Pharmaceutical Manufacturers Association of Japan (PAPJ) submitted "Proposal from the Pharmaceutical Industry for the G7 Health Ministers Meeting" to the Minister of Health, Labour and Welfare.
Statement for the G7 Ise-Shima Summit
The Pharmaceutical Manufacturers Association of Japan (PAPJ) submitted a "Request for the Health Agenda of the G7 Ise-Shima Summit" to the Minister of Health, Labour and Welfare.
Counterfeit Medicines
The Pharmaceutical Manufacturers Association of Japan (PMAJ) works to protect patients from the threat of counterfeit medicines made to look like real medicines.
Intellectual Property Rights
The JPMA works to increase understanding of the important role that intellectual property rights play in the creation and research and development of new medicines, as well as in improving access to medicines.
Universal Health Coverage (UHC)
We closely monitor the setting of the United Nations Post-2015 Sustainable Development Goals and recognize the significant contribution UHC can make to the wealth and economic productivity of countries in the Post-2015 Sustainable Development Goals.